Compare Summit Therapeutics Inc (SMMT) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs US Bancorp — how do they compare? Summit Therapeutics Inc trades at $15.16 (market cap $12.06B), while US Bancorp trades at $65.02 (market cap $100.17B). The key difference: US Bancorp is far larger — about 8.3× Summit Therapeutics Inc's market cap, and US Bancorp pays a 3.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | USB | |
|---|---|---|
Market Cap | $12.06B | $100.17B |
Sector | Health | Financials |
52-Week High | $26.98 | $65.02 |
52-Week Low | $12.55 | $45.28 |
Enterprise Value | $11.39B | — |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
U.S. Bancorp (USB) trades at $64.95, up 1.18% today, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 12.83 and net income margin of 27.61%, while recent quarters have consistently beaten earnings estimates. Positive sentiment is driven by upbeat Q2 2026 results and analyst upgrades, though RSI levels indicate potential overbought conditions near-term.
The outlook remains favorable with a consensus price target of $70.27, implying 8% upside, supported by dividend stability and lending growth. Risks include interest rate sensitivity and insider selling, but institutional accumulation and robust profitability underpin a constructive view for investors seeking value in regional banking.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
